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Abstract 
 
 
 
 Vascular endothelial dysfunction is a component of many chronic illnesses such 
as cardiovascular disease, diabetes, and hypertension. This dysfunction is initiated by an 
inflammatory response triggering an increase in leukocyte endothelial interactions.  It is 
characterized by increased oxidative stress often associated with reduced endothelial-
derived nitric oxide (NO) bioavailability.  Activation of NADPH oxidase is a major 
source of oxidative stress.  NADPH oxidase has five NOX and two Doux isoforms.  
NOX1 is expressed on vascular endothelial and smooth muscle cells, but is not expressed 
on neutrophils. Therefore, the role of NOX1 in inflammation is not completely clear. A 
NOX1 selective inhibitor, 2-acetylphenothiazine (ML171), was used to determine its 
effects on NG-nitro-L-arginine methyl ester (L-NAME)-induced leukocyte endothelial 
interactions in rat post capillary venules using intravital microscopy. We found that 50 
M L-NAME, a NO synthase inhibitor, significantly increased leukocyte rolling, 
adherence, and transmigration after a 2 hour superfusion of post capillary venules 
compared to the Krebs’ buffer control rats. However, ML171 was able to significantly 
attenuate L-NAME induced leukocyte-endothelial interactions compared to L-NAME 
alone.  Superfusion of post capillary venules with L-NAME and 0.2 M or 1.0 M 
ML171 reduced the leukocyte rolling from 71±8 cells/minute to 19±5 and 25±5 
cells/minute, respectively, adherence from 16±4 cells/minute to 3±1 cells/minute, and 
transmigration from 15±3 cells to 4±1 cells (both ML171 concentrations) over a 2 hour 
period.  The results obtained from intravital microscopy were confirmed through 
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Hematoxylin & Eosin (H&E) staining of superfused mensenteric tissues from 
experimental groups. We found that post capillary venules superfused with L-NAME 
exhibited significantly more leukocyte vascular adherence and tissue transmigration 
compared to Krebs’s control tissue.  The addition of 0.2 M or 1 M ML171 during the 
superfusion was found to significantly attenuate both L-NAME induced adherence and 
transmigration, reducing cell attachment from 269±11 cells/mm2  to 114±9 and 137±21 
cells/mm2, respectively, and transmigration from 505±60 cells/mm2 to 171±6 and 202±19 
cells/mm2, respectively.  Moreover, Hematoxylin & Eosin staining supported the 
observation that ML171 alone did not affect basal leukocyte-endothelial interactions. In 
summary, our data suggest that L-NAME induced leukocyte-endothelial interactions 
involves activation of NOX1.  ML171 may mitigate vascular endothelial dysfunction 
induced-inflammatory responses and elicit protective effects against chronic 
inflammation in the pathogenesis of various disease.
 3 
Introduction 
 
 
 
1. Vascular Endothelial Function  
 
 
 
Vascular endothelium plays a crucial role in bodily homeostasis, providing a 
physical barrier between blood and tissues and regulating many physiological functions 
such as control of vasculature tone through the release of vasoactive molecules that can 
either relax or constrict the blood vessels (1,2).  Vascular endothelium also plays a role in 
both innate and adaptive immunity through leukocyte-endothelial interactions involving 
leukocyte recruitment and transmigration in order to mitigate potential pathogens (1,2,3). 
Endothelial cells have the ability to metabolize, synthesize, and release a variety of 
substances, including vasoactive chemicals, nitric oxide (NO) and angiotensin II (Ang II), 
involved in vasodilation and vasoconstriction, respectively.  Endothelial cells are able to 
upregulate substances participating in inflammatory responses such as P-selectin and 
ICAM-1 required to slow passing leukocytes and adhere them to the vasculature.  
Endothelial cells participate in the production of reactive oxygen species (ROS) such as 
superoxide (SO) produced by NADPH oxidase, uncoupled eNOS, xanthine oxidase, and 
the mitochondrial respiratory chain.  SO produced under normal physiological conditions 
plays a role in endothelial cell signaling.  Endothelial cells are also able to produce 
procoagulants such as Von Willebrand factor which plays a role in platelet adhesion, and 
anticoagulants such as prostacyclin and NO, which inhibit platelet activation and promote 
 4 
vasodilation (1,2,4).  In particular, endothelial-derived NO and NADPH oxidase play 
critical roles in normal vascular endothelial functions. 
 
1.1) Endothelial-Derived NO 
 
 
 
NO is an endothelium derived relaxing factor with profound vasodilatory effects that 
can affect both the function and structure of the underlying vascular smooth muscle (1).  In 
the vasculature, NO is constitutively synthesized from L-arginine by nitric oxide synthase 
(NOS) (5). There are three isoenzymes of NOS: neuronal NOS (nNOS), inducible NOS 
(iNOS), and endothelial NOS (eNOS), however, in the vasculature, the main NOS 
isoenzyme contributing to NO production is eNOS (6). NO production can be induced 
through increased blood flow (sheer stress) or the binding of vasoactive substances such as 
acetylcholine, bradykinin, and adenosine to endothelial cell receptors causing an increase 
in intracellular calcium levels (7). In response to elevated levels of intracellular calcium, 
calmodulin binds to eNOS, which then catalyzes the conversion of L-arginine to L-
citrulline + NO (7).  In order for this reaction to occur, a number of cofactors for eNOS 
must be present, including tetrahydrobiopterin (BH4), FAD, FMN, and iron protoporphyrin 
IX (haem) (8).  Arguably, BH4 is most closely related to NO bioavailability due to its ability 
to stabilize the eNOS dimer formation.  If the eNOS dimer is not stabilized by BH4 it will 
favor the production of SO and thereby reduce the bioavailability of NO produced by eNOS 
(9).  NO produced from eNOS diffuses locally in endothelial cells to the luminal surface 
where it activates guanylate cyclase in smooth muscle cells causing the conversion of GTP 
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to cGMP, resulting in the inhibition of calcium into the smooth muscle cell and ultimately 
leading to vasodilation mediated by the smooth muscle cell, as shown in figure 1 (7).   
      In addition to being a potent direct vasodilator, NO also indirectly promotes 
vasodilation through the inhibition of AT1 receptor expression.  NO and Ang II have 
several antagonist effects on each other.  Ang II acts on its receptor AT1 to stimulate NO 
production and in return NO down-regulates the AT1 receptor indicating a balance between 
NO and Ang II (10). NO also is able to induce an anti-platelet effect through the reduction 
of intracellular calcium levels.  Since platelet aggregation is dependent on an increase in 
intracellular calcium, the reduction of intracellular calcium in platelets, through increased 
levels of cGMP, ultimately results in an anti-platelet effect (11).  Additionally, NO is able 
to produce an anti-inflammatory effect through its ability to inhibit leukocyte-endothelial 
interactions on the vascular wall (11).  Leukocyte endothelial interactions are dependent 
on the expression of adhesion molecules on the vasculature cell surface.  NO has been 
shown to prevent the expression of P-selectin on the vascular cell surface which is needed 
for leukocyte rolling to occur (12).   
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Figure 1:  Activation of eNOS. Sheer force and the binding of acetylcholine to G-protein receptors causes 
an increase in intracellular calcium.  Calcium is thereby able to activate calmodulin which binds to eNOS, 
activating it, and allowing the conversion of L-arginine to L-citrulline + Nitric Oxide (NO).  NO is able to 
diffuse to smooth muscles cells activating guanylate cyclase causing the conversion of GTP to cGMP.  cGMP 
further results in the inhibition of calcium into the smooth muscle cell, causing vasodilation.  Figure adapted 
from (7). 
 
 
 
1.2) NADPH Oxidase 
 
 
 
The NADPH oxidase family of enzymes, also known as NOX have 7 different 
isoforms: NOX1, NOX2, NOX3, NOX4, NOX5, Duox1, and Duox2 (13).  The expression 
of the NOX isoforms varies throughout the body, with NOX1-5 known to be expressed on 
the endothelial cells, NOX2 being expressed on leukocytes and Duox1 and Duox2 being 
expressed on epithelium (14).  NOX enzymes are a multisubunit enzyme, consisting of 
cytosolic subunits, NOXO1 (organizer subunit), NOXA1 (activator subunit) and RAC1 
(regulator), as well as membrane bound subunit, phox22, and membrane bound catalytic 
unit NOX (figure 2).  Under normal physiological conditions, the NOX enzymes are 
responsible for catalyzing the transfer of an electron from NADPH to O2 resulting in the 
production of SO (14). The SO produced from the NOX enzyme have different functions 
depending on the location of the NOX isoenzyme, but is known to be involved in the 
respiratory burst in phagocytes as well as involved in a myriad of signaling pathways such 
as cell migration and upregulation/surface expression of epidermal growth factor receptor 
(14).  The O2
- produced from the NOX enzymes is unstable and reacts quickly with 
superoxide dismutase (SOD) to form the more stable hydrogen peroxide (H2O2).  In select 
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NOX isoforms, such as NOX4, H2O2 is a direct product from the catalytic subunit (15).  
H2O2 is able to further act as a signaling molecule and is able to diffuse from the cell, unlike 
SO, rendering it useful in normal physiological conditions, however, can also lead to lipid 
peroxidation of cell membranes under excessive productions such as ischemia-
reproduction injury (16).  
 
 
 
Figure 2.  NADPH oxidase structure. NADPH oxidase activation requires the assembly of cytosolic 
subunits (RAC1, NOXA1, and NOXO1) and membrane subunits (p22phox and the catalytic subunit 
[NOX1]) on the cell membrane. All subunits facilitate the transfer of an electron from NADPH to O2 to 
produce superoxide (O2-). Figure adapted and modified from (17). 
2. Endothelial Dysfunction  
 
 
 
Vascular endothelial dysfunction is considered an essential clinical event in many 
illnesses such as cardiovascular disease, diabetes, and hypertension. Therefore, it is 
important to understand the underlying mechanisms causing vascular endothelial 
dysfunction in order to provide new clinical treatments (1).   
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In a state of dysfunction, the endothelium becomes activated and predisposed to 
vasoconstriction, leukocyte adhesion, and inflammation due to loss of balance in 
homeostasis, leading to the pathogenesis of cardiovascular disease (2).  The major 
characteristics of vascular endothelial dysfunction are increased oxidative stress and/or 
reduced endothelial-derived NO bioavailability. 
      Oxidative stress occurs when the amount of ROS present in the cell outweighs the cells 
ability to convert the ROS into less harmful substances, such as SO.  Normally, SO is then 
converted to H2O2 via SOD, and the further conversion of H2O2 to H2O via catalase.  
Inappropriate amounts of ROS present in a cell can cause alterations in membranes, DNA, 
and proteins as well as interfere with intracellular cascades resulting in altered protein 
activity which can be implicated in the pathophysiology of disease (18). During vascular 
damage in hypertension, ROS influences vascular remodeling by causing an increase in 
proteins, such as collagen, to be present on the extra cellular matrix (ECM) (19). 
Overproduction of SO can further be implicated in vascular endothelial dysfunction 
through direct quenching of endothelial-derived NO to form peroxynitrite (ONOO-). There 
are four major sources of oxidative stress: mitochondrial respiratory chain, xanthine 
oxidase, uncoupled eNOS, and NADPH oxidase. 
 
 
2.1) Mitochondrial Respiratory Chain 
 
 
 
In the mitochondrial respiratory chain, SO is produced through the reduction of O2, 
caused by electron leakage from the oxidative phosphorylation pathway (20).  Under 
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physiological conditions, SO is produced in small amounts mainly from complex I and 
complex III of the mitochondrial respiratory chain as electrons “leak” to O2 creating SO 
(21).  The SO is quickly converted via SOD to H2O2.  However, under some pathological 
conditions, such as ischemia, SO production can be increased in the respiratory chain from 
complex III, possibly due to the inhibition of complex IV.  In other conditions where 
NADPH is activated, mitoKATP channels are opened, resulting in mild mitochondrial 
uncoupling (21).  The increase in SO production from the mitochondrial respiratory chain 
will cause the further upregulation of NADPH oxidase and continue the cycle of increased 
SO production.  
 
2.2) Xanthine Oxidase 
 
Xanthine oxidase is expressed on the luminal surface of epithelial cells and is another 
source of SO produced as a byproduct of the conversion of hypoxanthine into urate (18).  
Xanthine oxidase is a unique source of SO because the enzyme is usually present as 
xanthine dehydrogenase which does not generate SO, however, it can be converted to 
xanthine oxidase through oxidation which can occur in the presence of cellular oxidative 
stress, thereby, amplifying SO production (18).   
 
2.3) eNOS Uncoupling/Downregulation  
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Uncoupling of eNOS is marked by a decrease in essential cofactor, 
tetrahydrobiopterin BH4, a critical cofactor in stabilizing the eNOS dimer. BH4 
bioavailability can be affected by increased oxidative stress resulting in the oxidation of 
BH4 to dihydrobiopterin (BH2), making the cofactor unusable to eNOS for the production 
of NO (22).  Uncoupled eNOS further promotes the production of SO, rather then the 
wanted NO, by not allowing the conversion of L-arginine to L-citrulline, ultimately 
increasing oxidative stress (22).  When there is an abundance of SO in the presence of NO, 
the two will react to form a peroxynitrite ion (13).  The peroxynitrite ion increases the 
uncoupling of eNOS through the conversion of BH4 to BH2 resulting in further reduction 
in the production of NO (13).  
In pathological conditions, eNOS can be downregulated by inflammatory cytokines such 
as TNF- through the inhibition of eNOS promoter activity and mRNA destabilization 
(23).  TNF- also leads to suppressed eNOS activity through the prevention of degradation 
of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of eNOS (23). 
 
2.4) Activated NADPH Oxidase 
 
      Activated NADPH oxidase is another source of SO acting by facilitating the transfer 
of an electron from NADPH to O2.  While NADPH has a role in normal physiological 
conditions, in pathological conditions, NADPH oxidase is upregulated to produce more 
SO.  Upregulation of NADPH oxidase occurring in pathological conditions begins with 
cytokines binding to G-protein receptors causing an increase in de novo synthesis of DAG.  
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Increase in PKC activity is further increased by diacylglycerol (DAG) and allows PKC to 
activate the RAC subunit of NADPH oxidase, facilitating the assembly and activation of 
the NOX enzyme.  Under basal conditions, the SO produced from the NOX enzyme is able 
to be converted to less harmful substances such as H2O2, however, under pathological 
conditions, through the upregulation of NOX, there is a marked increase in SO production, 
outweighing the cells ability to convert it to a less harmful substance.  SO, readily reacts 
with other ROS, mainly NO, to form the peroxynitrite ion, resulting in the uncoupling of 
eNOS, promoting the production of SO rather then the desired NO through the inability to 
convert L-arginine to L-citrulline + NO (22).  Therefore, the increase in NOX activation 
continues to contribute to the pathological state, and ultimately the continued upregulation 
of NOX, forming a deleterious cycle.   
 
 
 
 
3. Inflammation 
 
3.1) Acute Inflammation  
 
        Acute inflammation begins immediately following an injury and is marked by 
increased blood flow, increased permeability of the capillaries, and migration of 
neutrophils from capillaries and venules into the interstitial space.  The migration of 
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neutrophils is marked by leukocyte-endothelial interactions through adhesion molecules 
promoting leukocyte rolling, adherence, and transmigration.  Leukocyte-endothelial 
adhesion molecules are placed into one of three categories: selections, integrins, and the 
immunoglobulin superfamily. (24,25).  Cytokines involved in acute inflammation such as 
IL-, IL-8, and TNF-, are able to upregulate processes needed for the migration of 
leukocytes into interstitial space.  
       The first stage of leukocyte migration is leukocyte rolling, mediated by a family of 
glycoproteins, termed selectins.  On leukocytes, L-selectin is constitutively expressed and 
is vital to leukocyte rolling on the inflamed or activated endothelium (25).  On the 
endothelial side, P-selectin is located in Weibel-Palade bodies of endothelium cells and can 
be upregulated to the exterior of the cell by humoral activators present during inflammation 
such as thrombin, histamine, and platelet factors (25). The interaction between L-selectin 
and P-selectin causes a rolling effect on the leukocytes, slowing them down in the blood 
stream, thereby rendering the endothelium sticky to passing leukocytes.   
      Once leukocytes are slowed, they can begin adhering to the endothelium.  L-selectin is 
shed from neutrophils and the CD11b/CD18 integrin is then upregulated to the neutrophil 
surface (25).  Cd11b/CD18 then interacts with ICAM-1, constitutively expressed on the 
surface of endothelial cells, thus creating a firm adherence to the vascular cell wall.  While 
ICAM-1 is constitutively expressed to a degree, it can be strongly upregulated by cytokines 
including IL-, IL-8, and TNF- (25).  
      Once leukocytes are firmly adhered they can then begin transmigrating through the 
vascular wall. Transmigration of leukocytes through the vascular cell wall is believed to 
 13 
be mediated by platelet-endothelial cell adhesion molecule, PECAM-1, which is 
constitutively expressed on the surface of both leukocytes and the vascular cell wall, with 
its density concentrated in cell junctions (25).  When leukocytes transmigrate into 
interstitial spaces, they then release ROS to kill invading pathogens.  While these steps are 
vital to combatting infection, they are also responsible for vascular endothelial dysfunction 
and inflammation. 
 
3.2) Chronic inflammation 
 
Chronic inflammation is characterized by the immune system’s inability to resolve 
a pathogen, a state mimicked in diseases in which vascular endothelial dysfunction is 
present.  Numerous studies have shown that chronic inflammation contributes in the 
pathogenesis of various vascular diseases, such as hypertension, vascular complication of 
diabetes, ischemia/reperfusion (I/R) injury, and atherosclerosis.  While in these diseases 
there is no pathogen to kill, the body mimics the conditions as if there was one, including 
the presence of cytokines in the blood.  One of the main contributors to prolonged 
endothelial dysfunction is the cytokine TNF-.  TNF- has been shown to be associated 
with a decrease in NO produced from eNOS, a main contributor to endothelial dysfunction 
(23).  TNF- works to inhibit eNOS promoter activity as well as mRNA destabilization.  
Moreover, TNF- upregulates NADPH oxidase as well as induces CAM expression on the 
vascular cell surface, further promoting the transmigration of leukocytes into the interstitial 
space (figure 3) (23).  The upregulation of NOX in states of chronic inflammation is 
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extremely harmful as it potentiates further endothelial dysfunction due to the excessive 
production of SO, creating a vicious cycle.  Therefore, studies have begun to look into 
NOX inhibition in the vasculature in order to attenuate vascular endothelial dysfunction.  
Studies into NOX2, an isoform present in both the vasculature and leukocytes, have found 
that blocking the catalytic subunit of the NOX enzyme is able to attenuate leukocyte 
endothelial interactions present in endothelial dysfunction such as rolling, adherence and 
transmigration (26). However, in the case of chronic inflammatory diseases, inappropriate 
leukocyte transmigration and release of ROS leads to tissue and organ damage.  Therefore, 
when treating chronic inflammatory disease, it may be potentially beneficial to prevent 
inappropriate leukocyte rolling, adherence, and transmigration, in an effort to prevent 
unwanted tissue damage, such as the case when using a NOX2 inhibitor (25,26).  
Additionally, inhibition of other NOX isoforms could be potentially beneficial in 
preventing endothelial dysfunction in chronic inflammatory diseases.  
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Figure 3: Mediators of endothelial dysfunction in inflammatory diseases. Binding of Tumor 
Necrosis Factor Alpha (TNF-α) to its receptor, Tumor Necrosis Factor Receptor (TNFR), leads to 
reduced eNOS protein expression by suppression of promoter activity and destabilized mRNA.  
TNFR increases expression of cellular adhesion molecules (ICAM-1) and NOX1.  mRNA 
upregulation is mediated by ROS.  eNOS uncoupling, mediated in part by ROS, is associated with 
reduced NO production and enhanced generation of ROS.  Figure modified and adapted from (23).  
 
4. Summary 
 
In summary, what is not clear: The role of NOX1 in vascular endothelial 
dysfunction. NOX1 is an NADPH oxidase isoform known to be present in the colon, 
vascular smooth muscle cells, and endothelial cells (14).  NOX1 is upregulated at the 
mRNA level and activated by vascular pathological stimuli, making it worthy to study in 
cases of vascular endothelial dysfunction.  NOX1 is a multisubunit enzyme, consisting of 
cytosolic subunits: NOXO1 (organizer subunit), NOXA1 (activator subunit) and RAC1 
(regulator), as well as membrane bound subunit, phox22, and membrane bound catalytic 
subunit NOX1 (27).  NOX1 is responsible for transferring an electron from NADPH to O2 
resulting in the formation of SO.  Moreover, ROS generated by NOX1 has been reported 
to contribute to a number of diseases involving inflammation, hypertension, and 
atherosclerosis (27).  
 
5. ML171 
 
          ML171:  2-acetylphenothiazine, referred to as ML171 (MW=241.31 g/mol, IC50 for 
NOX1=0.25 μM), is a specific NOX1 inhibitor (28) (Figure 4).  While the exact mechanism 
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of action for ML171 is not known, studies have shown that an over expression of the NOX1 
catalytic subunit in the presence of ML171 can recover ROS production (27).  This result 
is not seen with an over expression of other NOX1 subunits, such as NOXO1 or NOXA1, 
suggesting that the method of action is a direct block on the NOX1 catalytic subunit (27).  
ML171 exhibits a 30-fold selectivity over other NOX isoforms, making it ideal to study 
the effects of blocking NOX1 in vascular endothelial dysfunction (27). 
 
 
 
Figure 4: ML171 Effects on NOX1.  ML171 inhibits the catalytic NOX1 subunit and attenuates SO release. 
Figure adapted and modified from (17). 
 
 
6. Hypothesis  
 
This study utilized intravital microscopy to analyze, in real time, in vivo, 
leukocyte endothelial interactions in postcapillary venules.  Interactions observed 
included leukocyte rolling, adherence, and transmigration.  Endothelial dysfunction was 
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induced using L-NAME, a non-selective NOS inhibitor.  It is hypothesized that: 1) The 
use of ML171, at varying doses, will significantly reduce the number of leukocyte 
rolling, adherence, and transmigration in the post capillary venule in which vascular 
endothelial dysfunction has been induced by L-NAME.  2) This reduction in leukocyte-
endothelial interactions will be confirmed using H&E staining on the superfused 
mesenteric tissue. 
Methods 
 
 
1. Intravital Microscopy 
 
Endothelial dysfunction plays a role in many chronic inflammatory diseases, 
therefore, the need for a real time, in vivo, method to study leukocyte-endothelial 
reactions in microcirculation is necessary.  Intravital microscopy provides a qualitative 
and quantitative technique for the study of leukocyte-endothelial interactions (29).  
Intravital microscopy also provides one of the best techniques to study authentic 
microcirculation interactions due to the tissue being left mainly intact, with only minor 
disruption caused by the surgical procedure necessary to unveil the tissue used.  
Utilization of this technique allows for the induction of various pathological conditions 
and conversely the study of how various drugs might affect those pathological conditions, 
as well as the effects various drugs may have.  
  
2. Experimental Setup 
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The use of rat mesenteric tissue in this study has been approved by the 
Institutional Animal Care and Use Committee of Philadelphia College of Osteopathic.  
Male Sprague-Dawley rats (Charles River, Springfield, NH), ranging from 275-325g in 
weight, were anesthetized with 60 mg/kg pentobarbital sodium through an intraperitoneal 
(i.p.) injection.  They were maintained using 30 mg/kg doses of pentobarbital sodium 
injected i.p. as needed. The left carotid artery was isolated and a PE-50 polyethylene 
catheter was inserted into the artery to allow for monitoring of mean arterial blood 
pressure (MABP) during the procedure via a BP-1 Pressure Monitor (World Precision 
Instruments (WPI), Sarasota, FL).  The abdominal cavity was then opened via a midline 
laparotomy.  A loop of ileal mesentery was selected and placed on a temperature 
controlled Plexiglass chamber, at 37ºC, held at a pH ranging from 7.3 -7.4. The tissue was 
superfused, with one of the experimental solutions outlined below, to allow for drug and 
buffer to be absorbed by the mesenteric tissue and enter into the vasculature. Mesenteric 
tissue that was subsequently placed over the Plexiglass pedestal was monitored for post 
capillary venule leukocyte-endothelial interactions via intravital microscopy (Nikon 
Corp., Tokyo, Japan); leukocyte trafficking was recorded using Image-Pro (Media 
Cybernetics, Inc., Bethesda, MD).  The experimental set up is pictured below in figure 5. 
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Figure 5: Intravital microscopy experimental set-up.  Side view (A) and front view (B) of experimental  
setup for intravital microscopy. 
The Krebs’ buffer was composed of the following in mmol/L: 118 NaCl, 4.47 
KCL, 2.45 CaCl2, 12.5 NaHCO3, and 1.19 KH2PO4.  The buffer was aerated with 95% N2 
and 5% CO2, and maintained at a pH of 7.3-7.4 at 37
oC.  Leukocyte-endothelial 
interactions were recorded in 2-minute intervals, beginning with a baseline, and then 
every 30 minutes after for 2 hours.  The recorded video was analyzed using the Image-
Pro recording software (Media Cybernetics, Inc., Bethesda, MD).  Leukocyte-endothelial 
interactions were assessed according to the following criteria: 1) Leukocytes were 
considered rolling if they were moving at a speed noticeably slower than that of red blood 
cells within the venule. 2) Leukocytes were considered adherent if they remain in a 
stationary position for >30 seconds in the length of a 100 μm venule.  3) Leukocytes were 
considered transmigrated if they were located in an area 20 x 100 μm2 adjacent to the 
postcapillary venule.  The numbers of leukocytes within each of these three categories 
were then quantified.  
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3. Treatment Groups 
 
 The experimental design consisted of five treatment groups (with 5-9 subjects in 
each group) for recording of leukocyte-endothelial interactions.  
Treatment groups: 
1. Krebs’ control: Krebs’ buffer was superfused for 2 hours following baseline 
recording to monitor basal leukocyte-endothelial interactions. 
2. Krebs’ + ML171 (1 μM): 1 μM ML171 in Krebs’ buffer was superfused after 
baseline recording to determine the effects of ML171 on basal leukocyte-
endothelial interactions. 
3. L-NAME (50 μM): L-NAME was superfused for 2 hours following baseline 
recording to determine if attenuation of vascular NO production could 
increase leukocyte-endothelial interactions. 
4. L-NAME (50 μM) + ML171 (0.2 μM): 50 μM of L-NAME with 0.2 μM 
ML171 was superfused after baseline recording to monitor the effect of a 
lower dose of ML171 on L-NAME induced-endothelial interactions. 
5. L-NAME (50 μM) + ML171 (1 μM): 50 μM of L-NAME with 1 μM ML171 
was superfused after baseline recording to monitor the effect of a higher dose 
of ML171 on L-NAME induced-endothelial interactions.  
 
4. Hematoxylin and Eosin Staining 
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At the end of the experiment, a section of the loop of ileal mesentery that was 
superfused was removed and stored in 4% paraformaldehyde for later histological 
analysis. 
Three representative sections of ileal mesentery from each experimental group 
(Krebs’ control, Krebs + 1 μM ML171, L-NAME, L-NAME + 0.2 μM ML171, and L-
NAME + 1 μM ML171) were selected for histological analysis.  The sections were 
chosen based on the leukocyte-endothelial interactions data which was closest to the 
mean values of the entire group.  The tissue was embedded in paraffin and sectioned into 
4.5 m serial sections and placed onto glass slides.  Sections were deparaffinized and 
rehydrated, then stained with H&E. Under light microscopy, areas containing 
venules/arterioles in the serosa connected to the mesentery were counted for leukocyte 
vascular adherence and transmigration into the tissue and expressed as adhered and 
transmigrated leukocytes/mm2.  
 
5. Statistical Analysis 
 
 All data is represented as means ± SEM.  The comparison of more than two 
groups was analyzed by ANOVA using post hoc analysis with the Bonferroni Dunn test 
to detect the differences among experimental groups within each aim.  Probability values 
of <0.05 are considered to be statistically significant.  
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Results 
 
 
1. Leukocyte-endothelial interactions via intravital microscopy 
 
1.1) Rolling 
 
 Figure 6 illustrates leukocyte rolling along the post capillary venule among the 
experimental groups.  There was no significant difference between baseline leukocyte 
rolling interactions among experimental groups.  The Krebs’ buffer did not significantly 
increase leukocyte rolling during the 120 min observation period and was maintained 
around 13±5 cells/minute (n=7).  By contrast, L-NAME significantly increased leukocyte 
rolling beginning at the 30-minute time period and lasting the remainder of the time 
interval.  At the end of the 2-hour time period, leukocyte rolling was increased to 71±8 
cells/minute (n=9, p<0.01) compared to the Krebs’ control.  The use of ML171, was able 
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to significantly attenuate the increase in leukocyte rolling induced by L-NAME.  The L-
NAME + ML171 0.2 μM group significantly attenuated leukocyte rolling at the 30-
minute time period, and continued to attenuate the leukocyte rolling throughout the 2-
hour time interval, reducing rolling to 19±5 cells/minute (n=5, p<0.05).  In addition, the 
L-NAME + ML171 1.0 μM group was able to significantly attenuate leukocyte rolling 
beginning at the 60-minute time period, and continued to attenuate the rolling throughout 
the 2-hour time interval, reducing rolling to 25±5 cells/minute (n=5, p<0.05).  In order to 
determine the whether ML171 directly influences basal leukocyte rolling, ML171(1 μM) 
was dissolved in Krebs’ buffer and superfused across the rodent mesentery.  There was 
no significant change in leukocyte rolling during the 2-hour observation when ML171 
was administered in the absence of L-NAME.   
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Figure 6: Leukocyte rolling among different experimental groups. L-NAME (50 µM) significantly 
increased leukocyte rolling from 30 min (#p<0.05, ##p<0.01 from Krebs’).  ML171 (0.2 µM and 1.0 µM) 
significantly attenuated L-NAME induced leukocyte rolling (*p<0.05, **p<0.01 from L-NAME).  
 
 
 
 
1.2) Adherence 
 
Figure 7 illustrates leukocyte adherence to the post capillary venule among the 
experimental groups.  There was no significant difference between baseline leukocyte 
adherence among the experimental groups.  The Krebs’ buffer did not significantly 
increase leukocyte adherence during the 120 min observation period and was maintained 
around 2±1 cells/100 μm (n=7).  By contrast, L-NAME significantly increased leukocyte 
adherence at the 60-minute time period and lasting the remainder of the time interval.  At 
the end of the 2-hour time period, leukocyte adherence was increased to 16±4 cells/100 
μm (n=9, p<0.01) compared to the Krebs’ control.  The use of ML171 (both 0.2 μM and 
1 μM), significantly attenuated L-NAME induced leukocyte adherence from 60-minute 
throughout the rest of experiment. Leukocyte adherence was 3±1 cells/100 μm [n=5, 
(p<0.05 for 0.2 μM;p<0.01 for 1.0 μM)]. There was no significant change in leukocyte 
adherence during the 2-hour observation when ML171 (1.0 μM) was administered in the 
absence of L-NAME.   
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Figure 7: Leukocyte adherence among different experimental groups. L-NAME (50 µM) significantly 
increased leukocyte adherence from 60 min (#p<0.05, ##p<0.01 from Krebs’).  ML171 (0.2 µM and 1.0 
µM) significantly attenuated L-NAME induced leukocyte adherence (*p<0.05, **p<0.01 from L-NAME). 
 
 
 
1.3) Transmigration  
 
      Figure 8 illustrates leukocyte transmigration from the post capillary venule into the 
tissue among the experimental groups.  There was no significant difference in leukocyte 
transmigration among the baseline recordings among the experimental groups.  The 
Krebs’ buffer did not significantly change leukocyte transmigration during the 2-hour 
recording period.  L-NAME significantly increased leukocyte transmigration beginning 
during the 60-minute time interval and lasting the remainder of the 2-hour time period.  
L-NAME increased transmigration 15±3 cells/20 x 100 μm2 (n=7, p<0.01) at the 2-hour 
time mark from the Krebs’ control 1±1 cells/minute (n=7, p<0.01).  The use of ML171 
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significantly attenuated the increase of leukocyte transmigration caused by L-NAME at 
the 90-minute time period for both the 0.2 μM and 1.0 μM. The L-NAME + ML171 (0.2 
μM and 1.0 μM) groups were able to attenuate the transmigration of leukocyte 4±1 
cells/20 x 100 μm2 compared to L-NAME [n=5, (p<0.01 for 0.2 μM; p<0.05 for1.0 μM)].).  
There was no significant change in leukocyte transmigration during the 2-hour 
observation when ML171 was administered in the absence of L-NAME.    
 
 
 
 
Figure 8. Leukocyte transmigration among different experimental groups. L-NAME (50 µM) 
significantly increased leukocyte transmigration from 60 min (##p<0.01 from Krebs’).  ML171 (0.2 µM 
and 1.0 µM) significantly attenuated L-NAME induced leukocyte transmigration (*p<0.05, **p<0.01 from 
L-NAME). 
 
 
 
 
2. Leukocyte Adherence and Transmigration via Hematoxylin and Eosin Staining 
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 The superfused rat mesenteric tissue that were harvested at the end of the 
experiment were assessed via hematoxylin and eosin (H&E) staining to calculate the 
density of leukocyte vascular adherence and tissue transmigration.  Figure 9 illustrates 
the representative leukocyte vascular adherence and tissue transmigration from 
experimental groups.  Figure 10 shows images of assessed tissues from each 
experimental group.  Results of the H&E staining were consistent to those obtained by in 
vivo intravital microscopy.  There was low leukocyte adherence (84±9 cells/mm2) and 
transmigration (129±35 cells/mm2) in the Krebs’ control group.  By contrast, the 50 µM 
L-NAME group exhibited a 3-fold increase in leukocyte adherence (269±11 cells/mm2, 
p<0.01) and 4-fold increase in leukocyte transmigration (505±59 cells/mm2, P<0.01) 
compared to Krebs’ buffer control.  50 µM L-NAME in the presence of 1 µM ML171 
however, reduced leukocyte adherence (137±21 cells/mm2) and transmigration (207±19 
cells/mm2).  Similar results were observed for 0.2 µM ML171 adherence (114±9 
cells/mm2) and transmigration (171±6 cells/mm2).   
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Figure 9. H&E Staining Data Summary. Summarized leukocyte adherence and transmigration by H&E 
staining of mesenteric tissues from all control groups.  Compared to Krebs’ control, the L-NAME treatment 
group significantly increased adherence and transmigration in leukocytes (##p<0.01 from Krebs’).  By 
contrast, both ML171 groups (0.2 µM and 1.0 µM) were able to significantly attenuate the increase in 
adherence and transmigration initiated by L-NAME. (**p<0.01 from L-NAME). 
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Discussion 
 
 
 
1. Summary of Major Findings  
 
 
 
 The major findings of this study are as follows: 1) 50  µM L-NAME significantly 
increased leukocyte-endothelial interactions compared to the Krebs’ control group.  2) 
The administration of ML171 in a concentration of either 0.2 µM or 1.0 µM, significantly 
attenuated the leukocyte rolling, adherence, and transmigration induced by L-NAME, 
which is further confirmed by results via H&E staining.  3) ML171 did not affect the 
basal leukocyte-endothelial interactions. 
 
2. Effects of L-NAME on Leukocyte-Endothelial Interactions 
 
 The superfusion of the Krebs’ buffer alone was not able to significantly increase 
leukocyte rolling, adherence, and transmigration suggesting that the surgical procedure 
Figure 10. H&E Staining Images. 
Representative pictures ( 20x, scale bar: 
20 μm) of leukocyte vascular adherence 
and tissue transmigration in mesenteric 
tissue  from Krebs’ control (A), L-
NAME (B), 1.0  µM ML171 (C), L-
NAME+ 0.2 µM ML171 (D) L-NAME+ 
1.0  µM ML171 (E) by H&E staining. > 
denotes adhered leukocyte.  denotes 
transmigrated leukocyte.  Arrows are 
representative leukocytes.  
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performed on the rodent to expose the mesenteric tissue did not initiate an intense 
inflammatory response.  By contrast, the addition of 50 µM of L-NAME to the Krebs’ 
buffer solution was able to significantly increase the leukocyte rolling, adherence, and 
transmigration beginning between the 30-60 minute intervals compared to the Krebs’ 
solution alone.  L-NAME competes with L-arginine to bind to eNOS, preventing the 
conversion of L-arginine to L-citrulline + NO via eNOS, ultimately leading to a decrease 
in NO bioavailability.  The use of L-NAME simulates the pathological state of 
endothelial dysfunction in vivo.  Previous studies by Lefer et al. have shown that the use 
of L-NAME upregulated P-selectin on endothelial cells from ~10% in untreated tissue to 
70-80% with the use of L-NAME, confirmed through immunostaining (15).  Once P-
selectin is upregulated on the endothelial cells, leukocytes can begin to slow down due to 
the interaction of P-Selectin with the L-selectin constitutively expressed on leukocytes.  
Once this interaction occurs, leukocytes are slowed and L-selectin is shed, causing the 
upregulation of Cd11b/CD18.  Cd11b/CD18 interacts with ICAM-1, constitutively 
expressed on the surface of endothelial cells, to create a firm adherence to the vascular 
cell wall.  While ICAM-1 is constitutively expressed, it can be upregulated in L-NAME 
induced inflammation by cytokines such as IL-, IL-8, and TNF- (25).  Previous studies 
in our lab found that superfusion of L-NAME for 2 hours significantly increased the 
expression of ICAM-1 on endothelial cells (26).  Therefore, the use of L-NAME in vivo 
induces a state of endothelial dysfunction, characterized by a marked increase in 
leukocyte-endothelial interaction, initiating a vicious inflammatory cycle.  
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3. Effects of ML171 on Leukocyte-Endothelial Interactions  
 
We did not observe any effect of ML171 on basal leukocyte-endothelial 
interactions suggesting that the constitutive activity of NOX1 has no significant impact 
on basal vascular endothelial function.  Under basal conditions, it does not appear that 
inhibition of NOX1 will disrupt cellular function, and the small amount of SO produced 
by NOX1 under basal conditions may mainly involve the signal transduction in 
vasculature, such as angiogenesis.  We found that ML171 significantly reduced L-NAME 
induced leukocyte-endothelial interactions.  L-NAME induces leukocyte-endothelial 
interactions through competitive inhibition of L-arginine, thereby, reducing NO 
bioavailability and inducing endothelial dysfunction like conditions.  Additionally, SO 
derived from NOX1 has been shown to accelerate the translocation of PKC which 
phosphorylates NOXO1, a cytosolic subunit of NOX1, thereby, increasing the amount of 
SO produced from NOX1 (30).  Furthermore, the SO produced by NOX1 has the ability 
to uncouple eNOS through the formation of the peroxynitrite ion.  The peroxynitrite ion 
then oxidizes BH4 to BH2 resulting in the inability of eNOS to use its cofactor BH4 (13).  
When the BH4 to BH2 ratio is increased, the product profile of eNOS is shifted to produce 
SO more so than NO, further reducing the bioavailability of NO, thereby, increasing 
endothelial dysfunction.  Our findings suggest that NOX1 may be upregulated during 
inflammation and promote eNOS uncoupling in addition to more PKC activation, 
resulting in further NADPH oxidase upregulation and subsequently more SO release. 
Therefore, blocking the movement of an electron from NADPH to O2 via ML171, may be 
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able to attenuate the inflammatory cycle present in the pathological state of endothelial 
dysfunction.  Additionally, a study by Weaver et. al found that the use of ML171 can 
produce anti-inflammatory effects in beta cells through the inhibition of cytokine induce 
production of ROS produced by NOX1 (23).  Cytokines play important role in 
upregulation of NOX1 assembly which can further amplify the damage of inflammation.  
We did not find any dose-dependent effects of ML171 (0.2 µM-1.0 µM) on L-
NAME induced leukocyte rolling, adherence, or transmigration.  However, in other 
studies, like the study mentioned above by Weaver et. al, a dose dependent effect of 
ML171 was observed.  Weaver et. al found that inflammatory cytokine induced beta cell 
death was reduced maximally at 10 µM and had a much more minimal effect at a dose of 
0.1 µM.  However, their study worked directly with cell models as well as a 
proinflammatory cytokine cocktail, providing a difficult comparison to our in vivo 
model.  The lack of a dose dependent effect could be due to a multitude of different 
factors such as using a live animal or the inability to determine the actual amount of drug 
concentration absorbed through the mesenteric tissue during each experiment.  
 
4. H&E Staining Compared to In Vivo Recording 
 
Data collected from the H&E staining shows a greater number of leukocyte 
transmigration among experimental groups than the number of leukocytes adhered, an 
opposite finding compared to that of the in vivo data in this study.  For leukocyte 
vascular adherence and tissue transmigration by H&E staining, our lab collected the 
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superfused mensenteric tissue and all types of blood vessels were included.  By contrast, 
in vivo, our lab record leukocyte-endothelial interactions in real-time by observing only 
one mesenteric postcapillary venule throughout experiments.  These differences in 
observation may have attributed to the differences among the data.  
 
 
 
5. Limitations 
 
The use of L-NAME in this study, a non selective NOS inhibitor inhibited all 
three forms of NOS (iNOS, nNOS, and eNOS), providing limitations to the study which 
aimed to induce vascular endothelial dysfunction by mainly reducing eNOS activity. 
However, it is worth noting that within a 2.5-hour experimental period, iNOS can not be 
induced and nNOS has minimal contribution to normal vascular endothelial function, 
therefore, the L-NAME induced inflammation was mainly caused by the inhibition of 
eNOS.  Moreover, L-NAME is a chemical and is not a disease related condition.  It has 
been well established that use of L-NAME provides a model of vascular endothelial 
dysfunction in vivo to study the underlying mechanisms involved in the subsequent 
inflammation.  Further limitations are encountered through the experimental model.  The 
superfusion of L-NAME only induces acute inflammatory conditions, whereas, diseases 
such as diabetes, hypertension, and atherosclerosis are chronic inflammatory diseases. 
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Therefore, it proves difficult to study long-term effects of the inhibition of ML171 using 
this model.  
 
6. Future studies 
 
Future studies are needed to learn more about NOX1’s role in processes involved 
in leukocyte-endothelial interactions, such as upregulation of adhesion molecules, and 
changes of PKC and other NOX isoforms 
7. Summary and Significance of Major Findings: 
 
In summary, our data demonstrates that the inhibition of NOX1 using ML171 is 
able to attenuate L-NAME induced leukocyte-endothelial interactions.  The mechanism 
of this action may be associated with reduced levels of SO, which help restore vascular 
endothelial function (37).  Our data suggest that the use of ML171 may be useful in 
attenuating vascular endothelial dysfunction and subsequent inflammation in chronic 
inflammatory diseases such as diabetes, hypertension and I/R injury.  
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